S&P Vs. Pharma Partnership Deal Volume
Pharma partnership deal volume was very positively correlated with the S&P Index for much of the past decade, but then followed an inverse correlation from around the time of the recession to the present day.
You may also be interested in...
Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.
Biolife4D CEO dropped president title and Cryo-Cell International co-chief executive officer dropped director title to open spots for new executives; Essex Bio-Technology deputy managing director was promoted to executive director; and more.
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.